A phase III trial of Vyxeos Liposome for Injection demonstrated statistically significant improvements in overall survival in patients with high-risk secondary acute myeloid leukemia.
Long-term data on patients treated with a standard chemoimmunotherapy combination show relapse rates dropped over time and 70% of patients were still alive 15 years later, with an overall cure rate estimated at 42% of patients treated, according to a study led by scientists at SWOG, Fred Hutch Cancer Center, and the University of Rochester Medical Center.
